ATTORNEY'S DOCKET NUMBER

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK		ATTORNEY'S DOCKET NUMBER				
OFFICE (MODIFIED)		X-15584 U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)				
TRANSMITTAL LETTER TO THE UNITED STATES		1				
DESIGNATED/ELECTED OFFICE (DO/EO/OS)		10/521137				
CONCERNING A FILING UNDER 35 U.S.C. 371		ATE PRIORITY DATE CLAIMED				
IN LEKINGTOWN TO TO TO TO	July 2003 (11.07.200)	3) 24 July 2002 (24.07.2002)				
. 101/052000						
TITLE OF INVENTION: DIHYDRO-DIBENZO[B.E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS						
Applicant herewith submits to the U.S. Designated/Elected Office (BC/EC/CO) and total						
This is a FIRST submission of items concerning a filing under 35 U.S.C. 3/1.						
This is a SECOND or SUBSEQUENT sul	bmission of items concerning	ig a filing under 35 U.S.C. 3/1.				
This express request to begin national exar	nination procedures (35 U.S	S.C. 371(f)) at any time rather than delay				
evenination until the expiration of the app	licable time limit set in 35 U	J.S.C. 371(b) and PCT Articles 22 and 39(1).				
4. X A proper Demand for International Prelim	inary Examination was mad	e by the 19th month from the earliest claimed				
priority date.						
5. X A copy of the International Application as	filed (35 U.S.C. 371(c)(2))					
a. is transmitted herewith (required	l only if not transmitted by	the International Bureau).				
has been transmitted by the Inte	rnational Bureau.	•				
c. X is not required, as the application	n was filed in the United St	ates Receiving Office (RO/US).				
Sales International Applicat	ion into English (35 U.S.C.	371(c)(2)).				
6. A translation of the line mational Application of the International Application of the Internation of the Interna	onal Application under PC	Γ Article 19 (35 U.S.C. 371 (c)(3))				
7. X Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) a. are transmitted herewith (required only if not transmitted by the International Bureau).						
1 1-1						
b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired.						
· ————————————————————————————————————						
d. X have not been made and will no	sime under PCT Article 19	(35 U.S.C. 371(c)(3)).				
8. A translation of the amendments to the cl	aims under FC1 Afficie 19	(35 6.12.6.1.1.4.7)				
9. An oath or declaration of the inventor(s)	(35 U.S.C. 3/1(c)(4)).	ha DCT Dequest Form				
10. X A declaration of the inventors 35 U.S.C.	371(c)(4) was provided in t	the feet Request Forms				
A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an						
English language translation of the annex Items 12. to 18. below concern document(s) or	tes to the IPER under PCT information included:	Article 36 (33 U.S.C. 371(c)(3)).				
12. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
13. X An assignment document for recording.	3. X An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
Assignment has been recorded at reel, frame						
15. X A FIRST preliminary amendment.						
A SECOND or SUBSEQUENT prelim	A SECOND or SUBSEQUENT preliminary amendment.					
16. A Sequence Listing, 1.821 Statement, a	· 					
17. X A power of attorney with attachment.	X A power of attorney with attachment.					
18. X Other items or information:						
Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for PCT/US2003/019554, filed 11 July 2003, which "This is the national phase application, under 35 USC 371, for PCT/US2003/019554, filed 11 July 2002." claims the benefit, under 35 USC 119(e), of US provisional application 60/398,538, filed 24 July 2002."						
[PAGE 1 OF 2]						

U.S. APPLICATION NO. (i	f known, see 37 C.F.R. 15)	INTERNATIONAL APPLICATION NO. PCT/US2003/019554 ATTORNEY'S DOCKET NUMBER X-15584					
		101/052	1005/01/254		LCULATIONS	PTO USE ONLY	
19. X The following Basic National St	g fees are submitted: age Fee =	\$ 300.00		CA	LCULATIONS	TTO USE ONET	
• National Stage So	earch Fee =	\$ 500.00					
National Stage Examination Fee = \$\frac{\$200.00}{\$1,000.00}\$ (a)							
Application Leng	th Fee						
Total Length (excluding sequence listings)							
$\underline{47}$ - 100 + 50 x 250 = $\underline{0}$ (b)							
٠.				L			
	ENTER AF	PPROPRIATE AMO	$\mathbf{DUNT} (\mathbf{a} + \mathbf{b}) =$	\$	1,000.00		
	for furnishing the oath	or declaration later than		\$			
from the earliest claims CLAIMS	ed priority date (37 CF NUMBER FILED	FR 1.492(e)). NUMBER EXTRA	RATE		-		
Total claims	24 -20=	NUMBER EATRA 4	X \$50.00	\$	200.00		
Independent claims	4 -3=	1	X \$200.00	\$	200.00		
MULTIPLE DEPEND	ENT CLAIM(S) (if ag	pplicable)	+ \$360.00	\$	200.00		
TOTAL OF ABOVE CALCULATIONS =				\$	400.00		
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity				\$			
Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				Ļ			
SUBTOTAL =				\$	1,400.00		
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							
TOTAL NATIONAL FEE =				\$	1,400.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be				\$	·		
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).							
\$40.00 per property							
		TOTAL FEES	ENCLOSED =	\$	1,400.00		
					Amount to be	\$	
					refunded charged	\$	
a A check in th	ne amount of \$	to cover the above fe	es is enclosed	L		Φ	
 a. A check in the amount of \$ to cover the above fees is enclosed. b. X Please charge my Deposit Account No. 05-0840 in the amount of \$1,400.00 to cover the above fees. A duplicate copy of this sheet is enclosed. 							
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any							
overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPO	NDENCE TO:	000					
ELI LILLY AND COM PATENT DIVISION	I LILLY AND COMPANY TENT DIVISION			E PETRON PORTO ROMAN ENTRE BRANCO PORTO			
P.O. BOX 6288							
/	INA 40200-0288	Gilbert T. Voy			25885		
	DATE NAME				PATENT TRADEMAR	_	
43,972	<u> </u>	(317) 276-296					
DECISTRATION	JUNIMBED	TELEDHONE NII	MRED				

IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicant(s): Owen Brendan Wallace

International Application No.: PCT/US2003/019554

Filed: 11 July 2003 (11.07.2003)

Invention:

DIHYDRO-DIBENZO[B.E]OXEPINE BASED SELECTIVE ESTROGEN

RECEPTOR MODULATORS, COMPOSITIONS AND METHODS

Lilly Reference:

X-15584

Earliest Priority Date: 24 July 2002 (24.07.2002)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number:	EL832954751US
Date of Deposit: 1-12-2005	

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper or fee)